Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Christopher Walker, B.S., Joshua J Oaks, B.S., Paolo Neviani, Ph.D, Jason G Harb, Ph.D., Ramasamy Santhanam, Ph.D, Y. Ma, Guido Marcucci, MD, James Van Brocklyn, Ph.D, Ching-Shih Chen, Ph.D, Robert Bittman, Ph.D, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 2901.

https://doi.org/10.1182/blood.V116.21.2901.2901

Published: 2010

Journal Articles

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, S. A Saddoughi, Christopher Walker, Paolo Neviani, Jason G Harb, Y. Ma, Srdan Verstovsek, MD, PhD, Guido Marcucci, MD, Roger Briesewitz, Robert Bittman, Ching-Shih Chen, Alfonso Quintas-Cardama, MD, Besim Ogretmen, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 775.

https://doi.org/10.1182/blood.V116.21.775.775

Published: 2010

Journal Articles

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Blood (2010) 116 (21): 515.

https://doi.org/10.1182/blood.V116.21.515.515

Published: 2010

Journal Articles

FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor.

Joshua Oaks, BS, Paolo Neviani, PhD, A. Mukhopadhyay, Ramasamy Santhanam, PhD, Y. Ma, Charlene Mao, Guido Marcucci, MD, Ching-Shih Chen, Jorge Cortes, MD, Michael A. Caligiuri, M.D., Peter Hokland, Sr., Claudia Huettner, PhD, Steffen Koschmieder, MD, Jose Cancelas, MD, PhD, Roger Briesewitz, PhD, Ravi Bhatia, MD, Denis-Claude Roy, MD, Besim Ogretmen, PhD, Danilo Perrotti, MD, PhD

Blood (2009) 114 (22): 3259.

https://doi.org/10.1182/blood.V114.22.3259.3259

Published: 2009

Journal Articles

The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells

Bruce Y. Ma, Sebastian A. Mikolajczak, Ali Danesh, Karoline A. Hosiawa, Cheryl M. Cameron, Akifumi Takaori-Kondo, Takashi Uchiyama, David J. Kelvin, Atsuo Ochi

Blood (2005) 106 (6): 2002–2010.

https://doi.org/10.1182/blood-2004-04-1622

Published: 2005

Journal Articles

p38 alpha MAP Kinase Inhibitor Inhibits Human Myeloma Cell Growth in Vivo.

Mamatha Reddy, M.S, Jing Y. Ma, M.D, Irene Kerr, A.A, Nirupama Henjarappa, B.S, Tony Navas, Ph.D, Jit Chakravarty, Ph.D, Sundeep Dugar, Ph.D, Linda S. Higgins, Ph.D, Andrew A. Protter, Ph.D, Satyanarayana Medicherla, Ph.D

Blood (2004) 104 (11): 4936.

https://doi.org/10.1182/blood.V104.11.4936.4936

Published: 2004

Journal Articles

Treatment of Relapsed Acute Promyelocytic Leukemia by Arsenic-Based Strategies without Hematopoietic Stem Cell Transplantation in Hong Kong: A Seven-Year Experience.

Wing Y. Au, MD, James C. Chim, MD, Albert K. Lie, MD, Cyrus R. Kumana, MD, Anskar Y. Leung, MD, Eric W. Tse, MD, Shing Y. Ma, MD, Raymond H. Liang, MD, Yok L. Kwong, MD

Blood (2004) 104 (11): 395.

https://doi.org/10.1182/blood.V104.11.395.395

Published: 2004

Journal Articles

Inhibition of p38 MAPK by SCIO-469 Suppresses TNF Generation and Promotes CD34+ Cell Survival in an In Vitro MDS Cell Culture Model.

Tony A. Navas, Ph.D., Aaron N. Nguyen, Ph.D., Jing Y. Ma, M.D., Elizabeth G. Stebbins, Ph.D., Edwin Haghnazari, Ph.D., Ruth Heaton, Alan F. List, M.D., Linda S. Higgins, Ph.D.

Blood (2004) 104 (11): 3424.

https://doi.org/10.1182/blood.V104.11.3424.3424

Published: 2004

Journal Articles

SCIO-469, a Potent and Selective Inhibitor of p38a MAPK, Normalizes the Bone Marrow Microenvironment and Inhibits Multiple Myeloma Cell Proliferation in In Vitro and In Vivo Models.

Aaron N. Nguyen, PhD, Mamatha Reddy, MS, Margaret Henson, MS, Elizabeth G. Stebbins, PhD, Gilbert O’Young, BS, Jing Y. Ma, MD, Edwin Haghnazari, PhD, Ann M. Kapoun, PhD, Satya Medicherla, PhD, Andy Protter, PhD, Tony A. Navas, PhD, Linda S. Higgins, PhD

Blood (2004) 104 (11): 1501.

https://doi.org/10.1182/blood.V104.11.1501.1501

Published: 2004

Journal Articles

Distinct temporal patterns of defensin mRNA regulation during drug- induced differentiation of human myeloid leukemia cells

S Herwig, Q Su, W Zhang, Y Ma, P Tempst

Blood (1996) 87 (1): 350–364.

https://doi.org/10.1182/blood.V87.1.350.350

Published: 1996

NARROW

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor.

The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells

p38 alpha MAP Kinase Inhibitor Inhibits Human Myeloma Cell Growth in Vivo.

Treatment of Relapsed Acute Promyelocytic Leukemia by Arsenic-Based Strategies without Hematopoietic Stem Cell Transplantation in Hong Kong: A Seven-Year Experience.

Inhibition of p38 MAPK by SCIO-469 Suppresses TNF Generation and Promotes CD34+ Cell Survival in an In Vitro MDS Cell Culture Model.

SCIO-469, a Potent and Selective Inhibitor of p38a MAPK, Normalizes the Bone Marrow Microenvironment and Inhibits Multiple Myeloma Cell Proliferation in In Vitro and In Vivo Models.

Distinct temporal patterns of defensin mRNA regulation during drug- induced differentiation of human myeloid leukemia cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only